The isolation of Venlafaxine from the biological material by hydrophilic solvents
DOI:
https://doi.org/10.24959/nphj.25.161Keywords:
Venlafaxine; biological material; isolation; TLC; UV spectrophotometryAbstract
Aim. To determine the Venlafaxine recovery from biological tissues using generally accepted methods of drug
isolation by the extraction with acidified water and acidified ethanol.
Materials and methods. The studies were performed on model samples of the animal liver spiked with Venlafaxine. The drug was isolated by the extraction with water acidified with oxalic acid according to the A. O. Vasylieva
method, ethanol acidified with oxalic acid by the Stas-Otto method, water acidified with sulfuric acid according to the
V. P. Kramarenko method. The extracts obtained were subjected to the additional cleanup procedure by the back-extraction and TLC. Detection and the quantitative determination of Venlafaxine in the extracts obtained were performed
by TLC and UV spectrophotometry.
Results and discussion. While extracting Venlafaxine from the biological material with water acidified with oxalic
acid, ethanol acidified with oxalic acid and water acidified with sulfuric acid, the recovery values were 44 ± 2 %, 36
± 3 % and 28 ± 3 %, respectively. The quantitative determination of the drug in extracts was performed by the UVspectrophotometric method at λmax 277 nm according to the equation of the calibration curve y=(0.00368 ± 2×10-5)×x,
which showed linearity in the range of the analyte concentrations of 25.00-300 μg/mL.
Conclusions. 1. The recovery values of Venlafaxine from the biological material using generally accepted methods have been determined. The highest recovery was obtained while extracting with water acidified with oxalic acid,
which was 44 ± 2 %, which provided its suitability for the sample preparation during the non-directed toxicological examination. 2. The inclusion of the additional cleanup procedure by the back-extraction and TLC into the pretreatment
process made possible to apply the UV spectrophotometric method, which was linear within the range of the expected
lethal concentrations of Venlafaxine in the biological material. 3. The method of the Venlafaxine isolation from the liver
tissue by extracting with acidified water with oxalic acid followed by the additional optimized cleanup procedure can
be recommended for the forensic toxicological examination of the biological material for the presence of Venlafaxine
References
Lense, X. M., Hiemke, C., Funk, C. S. M., Havemann-Reinecke, U., Hefner, G., Menke, A., Mössner, R., Riemer, T. G., Scherf-Clavel,
M., Schoretsanitis, G., Gründer, G., & Hart, X. M. (2023). Venlafaxine’s therapeutic reference range in the treatment of depression
revised: a systematic review and meta-analysis. Psychopharmacology, 241(2), 275-289. https://doi.org/10.1007/s00213-023-06484-7.
Suwała, J., Machowska, M., & Wiela-Hojeńska, A. (2019). Venlafaxine pharmacogenetics: a comprehensive review. Pharmacogenomics, 20(11), 829-845. https://doi.org/10.2217/pgs-2019-0031.60 ISSN 2415-8844 (Online) ВІСНИК ФАРМАЦІЇ 1 (109) 2025
Furukawa, T. A., Cipriani, A., Cowen, P. J., Leucht, S., Egger, M., & Salanti, G. (2019). Optimal dose of selective serotonin reuptake
inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. The Lancet Psychiatry, 6(7), 601-609. https://doi.org/10.1016/s2215-0366(19)30217-2.
Coutens, B., Yrondi, A., Rampon, C., & Guiard, B. P. (2022). Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine. Psychopharmacology, 239(9), 2735-2752. https://doi.org/10.1007/s00213-022-06203-8.
Aldosary, F., Norris, S., Tremblay, P., James, J. S., Ritchie, J. C., & Blier, P. (2021). Differential Potency of Venlafaxine, Paroxetine, and
Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients with Major Depressive Disorder. International Journal of
Neuropsychopharmacology, 25(4), 283-292. https://doi.org/ 10.1093/ijnp/pyab086.
Fagiolini, A., Cardoner, N., Pırıldar, S., Ittsakul, P., Ng, B., Duailibi, K., & El Hindy, N. (2023). Moving from serotonin to serotoninnorepinephrine enhancement with increasing venlafaxine dose: Clinical implications and strategies for a successful outcome in major
depressive disorder. Expert Opinion on Pharmacotherapy, 24(15), 171-1723. https://doi.org/ 10.1080/14656566.2023.2242264.
Aiyer, R., Barkin, R. L., & Bhatia, A. (2016). Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review. Pain Medicine,
(10), 1999-2012. https://doi.org/10.1093/pm/pnw261.
Pandey, A., Price, A., Ayala-Lopez, N., Garza, K., Marzinke, M. A., & Knezevic, C. E. (2024). Multiplexed Quantification of Venlafaxine and Metabolites in Human Plasma by Liquid Chromatography-Tandem Mass Spectrometry. Journal of Pharmaceutical and
Biomedical Analysis, 243, 116082. https://doi.org/10.1016/j.jpba.2024.116082.
Holland, J., & Brown, R. (2017). Neonatal venlafaxine discontinuation syndrome: A mini-review. European Journal of Paediatric Neurology, 21(2), 264-268. https://doi.org/10.1016/j.ejpn.2016.11.003.
Venlafaxine: more dangerous than most «selective» serotonergic antidepressants. (2016). Prescrire International, 25(170), 96-99.
PMID: 27186622.
Tuman, T. C. (2021). Venlafaxine-Induced Urinary Retention. The Primary Care Companion For CNS Disorders, 23(1), 20l02702.
https://doi.org/10.4088/pcc.20l02702.
Francesconi, G., Orsolini, L., Papanti, D., Corkery, J. M., & Schifano, F. (2015). Venlafaxine as the ‘baby ecstasy’? Literature overview
and analysis of web-based misusers′ experiences. Human Psychopharmacology: Clinical and Experimental, 30(4), 255-261. https://doi.
org/10.1002/hup.2476.
Moffat, A. C., Osselton, M. D., & Widdop, B. (2011). Clarke’s analysis of drugs and poisons in pharmaceuticals, body fluids and postmortem material. (4th ed.). London, Chicago: Pharmaceutical Press.
Baselt C. R. (2011). Disposition of Toxic Drugs and Chemicals in Man. (9th ed.). Seal Beach, California: Biomedical Publications.
Alibegović, A., Kariž, S., & Volavšek, M. (2019). Fatal overdose with a combination of SNRIs venlafaxine and duloxetine. Forensic
Science, Medicine and Pathology, 15(2), 258-261. https://doi.org/10.1007/s12024-019-00097-3.
Pedersen, J. S., & Munck, L. K. (2014). Dødelig venlafaxin forgiftning [A fatal overdose of venlafaxine]. Ugeskr Laeger, 176(9A),
V09130539. PMID: 25350413.
Miranda, L. F. C., Domingues, D. S., & Queiroz, M. E. C. (2016). Selective solid-phase extraction using molecularly imprinted polymers for analysis of venlafaxine, O-desmethylvenlafaxine, and N-desmethylvenlafaxine in plasma samples by liquid chromatographytandem mass spectrometry. Journal of Chromatography A, 1458, 46-53. https://doi.org/10.1016/j.chroma.2016.06.024.
Baiurka, S., & Karpushyna, S. (2013). Detection and determination of venlafaxine in liver tissue by colour tests, TLC, UV-spectroscopy,
HPLC with multi-wave detection. Journal of Chemical and Pharmaceutical Sciences, 5(12), 1110-1120. https://surl.li/raanpx.
Dziurkowska, E., & Wesołowski, M. (2013). Techniki ekstrakcyjne w analizie wenlafaksyny i jej metabolitów w materiale biologicznym [Extraction techniques for analysis of venlafaxine and its metabolites in biological matrices]. Psychiatria Polska, 47(5), 909-920.
PMID: 25011236.
Savchenko, M. A., & Chubenko, V. O. (2024). Nastanova shchodo provedennia sudovo-toksykolohichnykh doslidzhen.
Osypchuk, L. I. (2020). Khimiko-toksykolohichne doslidzhennia syldenafilu, vardenafilu ta yikh metabolitiv pry kombinovanykh otruienniakh [Dys. na zdobuttia stup. kand. nauk.] https://uacademic.info/ua/document/0420U102354#.
Tomarovska, L. Yu. (2021). Khimiko-toksykolohichne doslidzhennia atomoksetynu [Dys. kand. farm. nauk., Natsionalnyi farmatsevtychnyi
universytet] https://surl.li/epxzjd.
ICH guideline Q2(R2) on validation of analytical procedures. 2022. https://surl.li/zpqtwc
Downloads
Published
Issue
Section
License
Copyright (c) 2025 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
